Real-world Healthcare Resource Use Research Articles

A Multi-Centre Retrospective Study To Describe The Impact on Healthcare Resource Use And Real World Effectiveness of Golimumab In Ankylosing Spondylitis (AS) In UK Clinical Practice

Objectives Study aims were to describe the impact of Tumour Necrosis Factor-α (TNF-α) inhibitor golimumab on UK real-world healthcare resource use (HRU) and evaluate the clinical effectiveness of golimumab in the treatment of Ankylosing Spondylitis (AS). This abstract presents HRU data for the 6 months pre- and post-golimumab initiation as well as effectiveness data at 6 months post-golimumab initiation compared with the closest observation pre-golimumab initiation. Methods This multicentre observational study of consenting adult patients was carried out via retrospective medical chart review in six UK NHS hospital rheumatology departments between November 2015 and October 2016. Inclusion criteria included AS diagnosis, anti-TNF-α-naive, received minimum three doses of golimumab for AS, and first dose at least 12 months before data collection. Effectiveness was measured using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Spinal Pain Visual Analogue Scale (VAS) and Bath Ankylosing Spondylitis Functional Index (BASFI). Patients with missing data are excluded from the effectiveness analysis. Results The study enrolled 47 eligible patients, 74% male, mean age of 46.4 years, mean golimumab treatment duration of 2.3 years. A significant reduction of 30.4% (Mann-Whitney p<0.005) in mean number of rheumatology clinic visits (from 2.3 to 1.6) and a 27.3% reduction in mean number of clinical investigations (from 13.4 to 9.7) over the 12-month period was observed (Mann-Whitney p<0.05). 74% (32/43) of patients achieved a clinically meaningful change (BASDAI score reduced by 2 or more), and overall mean BASDAI score reduced by 3.9 points [n=43] (Mann-Whitney p<0.001). 75% (18/24) of patients achieved a reduction in spinal pain VAS by 2cm or more indicating a treatment response. Overall mean BASFI score improved by 4.1 points [n=26] (Mann-Whitney p<0.001). Conclusions Golimumab was associated with statistically significant reductions in HRU and clinically meaningful improvements in UK patients with AS during the first 6 months of treatment.

Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis of the EPICOR registry

ObjectiveThe aim of this report is to provide insight into real-world healthcare resource use (HCRU) during the critical management of patients surviving acute coronary syndromes (ACS), using data from EPICOR...

Health care resource use (HRU) with nonplatinum chemotherapy for previously treated advanced ovarian cancer (aOC): Findings from SEER-Medicare data.

e15539 Background: Real world HRU in second-line aOC has not been well quantified. The objective of this study was to assess HRU and treatment patterns in women with previously-treated aOC subsequently treated with nonplatinum chemotherapy (CT). Methods: A retrospective study was conducted using the SEER-Medicare linked dataset. The population included women ≥ 65 years who were diagnosed with incident, distant-stage aOC between 1993-2005 and who had ≥ 3 months of claims data before diagnosis. The study cohort included patients previously treated with platinum-based CT and re-treated following a ≥ 90 day treatment-free interval (TFI) with nonplatinum-based CT in 2000-2005. Patients were followed from the first claim for retreatment with a nonplatinum CT regimen until either death or the end of the claims data (12/31/2007). Measures of HRU included hospitalizations, outpatient visits, physician visits, hospice care, home health care, and skilled nursing facility (SNF) visits. Costs of each HRU event were estimated by summing all Medicare payments, primary insurer payments, patient copayments and deductibles for services in the claims files. Average healthcare costs per patient per event type (e.g., hospitalization) are calculated as total event cost per event divided by number of patients with the event. Results: 2,166 previously treated aOC patients subsequently received nonplatinum CT as second-line therapy. Mean age was 74.0 years (SD 5.6). The mean treatment duration in the non- platinum CT period was 317 days (SD 354). Paclitaxel and pegylated liposomal doxorubicin (PLD) were the most commonly used nonplatinum CT agents. Paclitaxel use declined from 38.1% to 30.0% while PLD use increased from 16.4% to 26.8% from 2000-2005. Rate of hospitalization was 1.3 per person-year. Mean hospitalization cost per patient was $10,466 (SD $10,846). Mean SNF and hospice care costs per patient were $7,416 (SD $6,907) and $6,955 (SD $11,416) respectively. Conclusions: Both paclitaxel and PLD were frequently used nonplatinum-based CTs in women with aOC who were previously treated with platinum-based agents. Hospitalization costs per patient were substantial. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen Amgen Amgen